Rivia Secures €13 Million in Series A Funding
Rivia, a Zurich-based startup specializing in AI-driven analytics for biotech clinical trials, has successfully raised €13 million in a Series A funding round. The company focuses on integrating fragmented clinical trial data to generate actionable insights, aiming to streamline operations and uncover new therapeutic potentials.
Investors and Leadership
The Series A round was spearheaded by Earlybird, with additional investments from Defiant, Speedinvest, Amino Collective, and Nina Capital. This influx of capital is expected to bolster Rivia's strategic initiatives.
Rivia was founded in 2022 by Erik Scalfaro, who serves as the CEO, and Tiago Kieliger, the CTO. Scalfaro commented on the company's progress, noting, "Two years ago, we made a deliberate decision. We started with the scaffolding, building the foundational data engine before turning to agents." This approach, he believes, provides Rivia with a structural advantage in the industry.
Strategic Use of Funds
The newly acquired funds will primarily be used to expand Rivia's team and scale its product development efforts. The company also plans to focus on international growth, with particular attention to the U.S. market, which represents a significant opportunity for expansion.
Industry Context
Rivia's platform is gaining traction at a time of increasing regulatory attention. Recent guidelines from the FDA emphasize proactive risk management and compliance, supporting innovation in clinical trial design and execution. This environment could potentially benefit Rivia's growth and adoption in the biotech sector.
As Rivia moves forward with its plans, the company continues to leverage its AI-driven platform to enhance the efficiency of bringing new drugs to market. With the backing of notable investors and a clear strategic vision, Rivia is well-positioned to make a significant impact in the biotech industry.